Screening for genital chlamydia infection

被引:45
|
作者
Low, Nicola [1 ]
Redmond, Shelagh [1 ]
Uuskula, Anneli [2 ]
van Bergen, Jan [3 ]
Ward, Helen [4 ]
Andersen, Berit [5 ]
Gotz, Hannelore [6 ]
机构
[1] Univ Bern, ISPM, Finkenhubelweg 11, CH-3012 Bern, Switzerland
[2] Univ Tartu, Dept Publ Hlth, Tartu, Estonia
[3] Univ Amsterdam, Dept Gen Practice & Family Med, Amsterdam, Netherlands
[4] Imperial Coll London, Dept Infect Dis Epidemiol, London, England
[5] Dept Publ Hlth Programmes, Randers, Denmark
[6] Rotterdam Rijnmond Publ Hlth Serv, Dept Infect Dis Control, Rotterdam, Netherlands
关键词
PELVIC-INFLAMMATORY-DISEASE; SEXUALLY-TRANSMITTED INFECTIONS; RANDOMIZED CONTROLLED-TRIAL; TUBAL FACTOR INFERTILITY; TRACHOMATIS INFECTION; GENERAL-PRACTICE; BACTERIAL VAGINOSIS; COST-EFFECTIVENESS; REINFECTION RATES; ECTOPIC PREGNANCY;
D O I
10.1002/14651858.CD010866.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Genital infections caused by Chlamydia trachomatis are the most prevalent bacterial sexually transmitted infection worldwide. Screening of sexually active young adults to detect and treat asymptomatic infections might reduce chlamydia transmission and prevent reproductive tract morbidity, particularly pelvic inflammatory disease (PID) in women, which can cause tubal infertility and ectopic pregnancy. Objectives To assess the effects and safety of chlamydia screening versus standard care on chlamydia transmission and infection complications in pregnant and non-pregnant women and in men. Search methods We searched the Cochrane Sexually Transmitted Infections Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, LILACS, CINAHL, DARE, PsycINFO and Web of Science electronic databases up to 14 February 2016, together with World Health Organization International Clinical Trials Registry (ICTRP) and ClinicalTrials.gov. We also handsearched conference proceedings, contacted trial authors and reviewed the reference lists of retrieved studies. Selection criteria Randomised controlled trials (RCTs) in adult women (non-pregnant and pregnant) and men comparing a chlamydia screening intervention with usual care and reporting on a primary outcome (C. trachomatis prevalence, PID in women, epididymitis in men or incidence of preterm delivery). We included non-randomised controlled clinical trials if there were no RCTs for a primary outcome. Data collection and analysis Two review authors independently assessed trials for inclusion, extracted data and assessed the risk of bias. We resolved disagreements by consensus or adjudication by a third reviewer. We described results in forest plots and conducted meta-analysis where appropriate using a fixed-effect model to estimate risk ratios (RR with 95% confidence intervals, CI) in intervention vs control groups. We conducted a pre-specified sensitivity analysis of the primary outcome, PID incidence, according to the risks of selection and detection bias. Main results We included six trials involving 359,078 adult women and men. One trial was at low risk of bias in all six specific domains assessed. Two trials examined the effect of multiple rounds of chlamydia screening on C. trachomatis transmission. A cluster-controlled trial in women and men in the general population in the Netherlands found no change in chlamydia test positivity after three yearly invitations (intervention 4.1% vs control 4.3%, RR 0.96, 95% CI 0.84 to 1.09, 1 trial, 317,304 participants at first screening invitation, low quality evidence). Uptake of the intervention was low (maximum 16%). A cluster-randomised trial in female sex workers in Peru found a reduction in chlamydia prevalence after four years (adjusted RR 0.72, 95% CI 0.54 to 0.98, 1 trial, 4465 participants, low quality evidence). Four RCTs examined the effect of chlamydia screening on PID in women 12 months after a single screening offer. In analysis of four trials according to the intention-to-treat principle, the risk of PID was lower in women in intervention than control groups, with little evidence of between-trial heterogeneity (RR 0.68, 95% CI 0.49 to 0.94, I-2 7%, 4 trials, 21,686 participants, moderate quality evidence). In a sensitivity analysis, the estimated effect of chlamydia screening in two RCTs at low risk of detection bias (RR 0.80, 95% CI 0.55 to 1.17) was compatible with no effect and was lower than in two RCTs at high or unclear risk of detection bias (RR 0.42, 95% CI 0.22 to 0.83). The risk of epididymitis in men invited for screening, 12 months after a single screening offer, was 20% lower risk for epididymitis than in those not invited; the confidence interval was wide and compatible with no effect (RR 0.80, 95% CI 0.45 to 1.42, 1 trial, 14,980 participants, very low quality evidence). We found no RCTs of the effects of chlamydia screening in pregnancy and no trials that measured the harms of chlamydia screening. Authors' conclusions Evidence about the effects of screening on C. trachomatis transmission is of low quality because of directness and risk of bias. There is moderate quality evidence that detection and treatment of chlamydia infection can reduce the risk of PID in women at individual level. There is an absence of RCT evidence about the effects of chlamydia screening in pregnancy. Future RCTs of chlamydia screening interventions should determine the effects of chlamydia screening in pregnancy, of repeated rounds of screening on the incidence of chlamydia-associated PID and chlamydia reinfection in general and high risk populations.
引用
收藏
页数:64
相关论文
共 50 条
  • [31] PREVENTION OF PULMONARY AND GENITAL CHLAMYDIA INFECTION BY ORAL IMMUNIZATION
    LASCOLEA, LJ
    CUI, ZD
    KOPTI, S
    FISHER, J
    OGRA, PL
    VACCINES FOR SEXUALLY TRANSMITTED DISEASES, 1989, : 86 - 91
  • [32] TREATMENT OF CHLAMYDIA-TRACHOMATIS GENITAL-INFECTION
    TOOMEY, KE
    BARNES, RC
    REVIEWS OF INFECTIOUS DISEASES, 1990, 12 : S645 - S655
  • [33] Antibiotic Use before Chlamydia and Gonorrhea Genital and Extragenital Screening in the Sexually Transmitted Infection Clinical Setting
    Dukers-Muijrers, Nicole H. T. M.
    van Liere, Genevieve A. F. S.
    Wolffs, Petra F. G.
    Den Heijer, Casper
    Werner, Marita I. L. S.
    Hoebe, Christian J. P. A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (01) : 121 - 128
  • [34] Genital Chlamydia trachomatis infection in women in a Nigerian hospital
    Harry, TC
    GENITOURINARY MEDICINE, 1997, 73 (04): : 326 - 326
  • [35] Which treatment for genital tract Chlamydia trachomatis infection?
    Tobin, JM
    Harindra, V
    Mani, R
    INTERNATIONAL JOURNAL OF STD & AIDS, 2004, 15 (11) : 737 - 739
  • [36] Pooling urine samples for ligase chain reaction screening for genital Chlamydia trachomatis infection in asymptomatic women
    Kacena, KA
    Quinn, SB
    Howell, MR
    Madico, GE
    Quinn, TC
    Gaydos, CA
    JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (02) : 481 - 485
  • [37] GENITAL CHLAMYDIA-TRACHOMATIS INFECTION IN AUSTRALIA - REPLY
    GARLAND, SM
    MEDICAL JOURNAL OF AUSTRALIA, 1993, 159 (09) : 639 - 640
  • [38] GENITAL CHLAMYDIA-TRACHOMATIS INFECTION IN AUSTRALIA - REPLY
    GARLAND, SM
    MEDICAL JOURNAL OF AUSTRALIA, 1994, 160 (01) : 46 - 46
  • [39] Chlamydia trachomatis genital infection in adolescents and young adults
    Darville, Toni
    HOT TOPICS IN INFECTION AND IMMUNITY IN CHILDREN III, 2006, 582 : 85 - 100
  • [40] QUANTITATIVE STUDY OF CHLAMYDIA TRACHOMATIS IN GENITAL-INFECTION
    MALLINSON, H
    ARYA, OP
    GODDARD, AD
    BRITISH JOURNAL OF VENEREAL DISEASES, 1982, 58 (01): : 36 - 39